Patritumab
Patritumab
Patritumab (pronunciation: puh-rih-TOO-mab) is a monoclonal antibody designed for the treatment of cancer. It is developed by Daiichi Sankyo, a global pharmaceutical company.
Etymology
The name "Patritumab" is derived from the Latin word "patria", meaning "fatherland", and "tumab", a common suffix for monoclonal antibodies. The name signifies the drug's origin and its function as an antibody.
Function
Patritumab works by targeting and inhibiting the HER3 (human epidermal growth factor receptor 3) protein, which is often overexpressed in certain types of cancer. By blocking this protein, Patritumab can help to slow down or stop the growth of cancer cells.
Clinical Trials
Patritumab has undergone several clinical trials to test its safety and efficacy in treating various types of cancer. These trials have shown promising results, with some patients experiencing significant improvements in their condition.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- HER3: A protein that is often overexpressed in certain types of cancer.
- Daiichi Sankyo: A global pharmaceutical company that develops and manufactures drugs like Patritumab.
- Clinical trials: Research studies that test how well new medical approaches work in people.
External links
- Medical encyclopedia article on Patritumab
- Wikipedia's article - Patritumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski